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The aryl hydrocarbon receptor (AHR) has long been studied by toxicologists as a ligand-
activated transcription factor that is activated by dioxin and other environmental pollutants
such as polycyclic aromatic hydrocarbons (PAHs). The hallmark of AHR activation is the
upregulation of the cytochrome P450 enzymes that metabolize many of these toxic com-
pounds. However, recent findings demonstrate that both exogenous and endogenous AHR
ligands can alter innate and adaptive immune responses including effects onT-cell differen-
tiation. Kynurenine, a tryptophan breakdown product, is one such endogenous ligand of the
AHR. Expression of indoleamine 2,3-dioxygenase by dendritic cells causes accumulation
of kynurenine and results in subsequent tolerogenic effects including increased regulatory
T-cell activity. At the same time, PAHs found in pollution enhanceTh17 differentiation in the
lungs of exposed mice via the AHR. In this perspective, we will discuss the importance
of the AHR in the immune system and the role this might play in normal physiology and
response to disease.
Keywords: indoleamine 2,3-dioxygenase,Th17 Cells,Treg cells, immunomodulation, kynurenine, aryl hydrocarbon
receptor
INTRODUCTION
Our laboratory has been actively investigating the role of the
aryl hydrocarbon receptor (AHR) in the immune system, and the
variable effects seen after binding endogenous and exogenous lig-
ands. Study of this receptor traditionally was in the domain of
toxicologists, as it was originally defined as a receptor to 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) (1). It was further identified
that additional toxins, including polycyclic aromatic hydrocarbons
(PAHs), also bind to the AHR (2–4). As the mechanism of AHR
activation and function was characterized, the importance of this
receptor as a transcription factor was realized. The AHR is a cytoso-
lic receptor that after binding migrates to the nucleus where it
becomes a transcription factor for cytochrome P450 genes that
encode enzymes that metabolize toxins, including those same tox-
ins that bind to the receptor (5). A connection to the immune
system had been previously recognized, primarily based on the
knowledge that exposure to TCDD led to rapid thymic involution,
and animals and human beings exposed to TCDD were known to
be immunosuppressed. Effects of TCDD on dendritic cells (DCs)
and T-cells have been recognized for years (6), and generation of
regulatory T-cells by an AHR-dependent mechanism was identi-
fied in 2005 (7). But in general, immunologists and those studying
autoimmunity did not become interested in the AHR until 2008,
when two high impact papers identified the role of the AHR in
T-cell differentiation, with certain ligands enhancing Treg genera-
tion, and others enhancing Th17 differentiation, both in vitro and
in vivo (8, 9). Since that time, there has been a flood of reports on
the role of the AHR in the adaptive immune system and animal
models of disease, particularly autoimmune disease (10–12).
The role of the AHR in responding to toxins is thought to have
evolved, as invertebrate forms of the AHR do not bind TCDD (13),
and the toxins associated with the AHR are man made and were
generated long after the origins of the receptor. It has been postu-
lated that the initial importance of the AHR was in embryologic
development, and in addition there was (and remains) a require-
ment for binding of this receptor to endogenous ligands early in
development. This is based on the abnormal phenotype of AHR
null mice that display a patent ductus venosus (14), as well as the
necessity for the hypomorphs to bind AHR ligand early in devel-
opment to prevent the patent ductus venosus in these transgenic
mice (15). In addition to binding to pollution and endogenous
ligands, the AHR binds to numerous ligands present in the diet
including flavonoids, which are ubiquitous in fruits and vegeta-
bles. There has been an ongoing search for relevant endogenous
ligands in animals and human beings.
Around the time that the AHR was first recognized to play
some role in the acquired immune system by toxicologists, immu-
nologists were investigating indoleamine 2,3-dioxygenase (IDO1),
initially recognized as the rate-limiting enzyme in tryptophan
metabolism. In 1998, it was reported that tryptophan catabolism
by IDO1 and other enzymes was responsible for prevention of
allogeneic fetal rejection in mice, and it was further revealed that
this enzyme was generated by DCs, and in some way increased
the differentiation of Tregs (16). The mechanism was unclear,
but the two leading theories were that either tryptophan depri-
vation from its metabolism decreased the generation and division
of effector cells (17), or certain breakdown products of trypto-
phan, termed kynurenines, were acting through some target on
T-cells or other cells to favor Treg differentiation (18, 19). In our
own lab, we considered the hypothesis that kynurenine or one of
its breakdown products was working through the AHR in T-cells
to enhance Treg generation. This was based on the knowledge
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FIGURE 1 | AHR ligands increase IDO1 expression in BMDCs. qRT-PCR
analysis of IDO1 mRNA expression in bone marrow-derived DCs treated for
48 h with IFN-γ (10µg/ml), CpG (2.5µM), TCDD (10 nM), FICZ (200 nM), or
kynurenine (50µM). Data are from three independent experiments.
that indoles and other tryptophan derivatives are often ligands of
this receptor, making kynurenine a good candidate as an endoge-
nous ligand. We identified that not only does kynurenine bind to
the AHR in the cytosol of T-cells and enhance Treg generation
in vitro but additionally kynurenine and other AHR ligands act
on BMDCs to upregulate IDO expression in an AHR-dependent
manner (20) (Figure 1). The effects of AHR ligands on differen-
tiation and function of natural versus induced Tregs has not yet
been delineated.
One of the controversial and yet unanswered questions about
the role of the AHR in the immune system is whether it is prob-
able that different ligands bind to the AHR and lead to different,
almost opposite outcomes,perhaps based on some conformational
change or transcription of different genes, a finding that would
almost be unprecedented in physiology. We theorize that some
combination of strength of binding, duration of binding, route
of exposure, and surrounding milieu determines whether Treg
or Th17 differentiation is enhanced. Although early experience
seemed to suggest that ligands were either “regulatory” (mean-
ing they favored differentiation of Tregs) or “effector” (mean-
ing they favored differentiation of effector Th17 cells) (8), more
recent studies and our own experience has suggested that this is
not likely the case. For instance, the ligand 6-formylindolo[3,2-
b]carbazole (FICZ) was first described as enhancing Th17 dif-
ferentiation in vitro and in vivo, and when administered subcuta-
neously worsened autoimmunity in an experimental autoimmune
encephalomyelitis (EAE) model in mice. However, it has recently
been shown that when this same ligand is administered intraperi-
toneally, Treg differentiation is favored and there is a reduction in
EAE disease severity (21, 22). Our own experience has also shown
that depending on the culture conditions or inflammatory status
of the animals, similar ligands can enhance either Th17 or Treg
generation. We have also found that every ligand we have tested
stimulates T-cells to generate IL-22, and it has been demonstrated
that the AHR is required for IL-22 generation in the majority of
scenarios (23–25). IL-22 is an interesting cytokine that is generated
by various types of T-cells, but its receptor is found on epithelial
cells. In general, IL-22 is thought to be protective against immune
damage and helpful in epithelial cell repair (26–28). We have
recently shown that particulate matter (PM) in the form of urban
dust particles (UDP) from the National Institute of Standards and
Technology (NIST; SRM1649b), containing PAHs, increases the
Th17 response both in the lung in vivo and in T-cells in vitro (29).
The in vitro response was shown to be AHR dependent. Therefore,
a connection between the AHR and the immune system seems
real, but the effects are complicated and dependent on the model
or conditions being examined. This relationship of the AHR with
the immune system, where binding of this receptor with differ-
ent ligands in differing milieus can lead to seemingly opposing
responses in T-cell differentiation has allowed us to come up with
the following hypothesis:
THE AHR AS A SENSOR
The AHR serves as a sensor that responds to signals, both from the
outside environment or internal milieu, to modulate an immune
response. In the setting of an endogenous immune response, the
AHR helps contain the inflammation and decreases collateral dam-
age, so the response does not cascade in strength and lead to
autoimmune destruction. In responding to exogenous ligands, the
AHR functions as a sensor to “danger” signals, such as dioxins,
PAHs, and other components of pollution. This is of evolutionary
benefit for individuals exposed to man-made pollution or other
toxins, as illustrated by the following scenario. When someone
is exposed to inhaled atmospheric pollution, damage to bacterial
clearance mechanisms and the epithelial lining of the airway puts
the individual at risk for endogenous bacterial invasion and acti-
vation of a reactive airway response. The AHR present in immune
cells residing in the lung binds to fractions of PM (PAHs and
others), leading to an enhancement of Th17 differentiation that
can serve as an immune barrier to the endogenous bacteria found
in the lining of the lung. Simultaneously, AHR activation leads
to generation of IL-22 that helps with epithelial cell repair and
maintenance of tight junctions. Finally, activation of the AHR
causes an upregulation of cytochrome P450 enzymes that metab-
olize the harmful toxicants. Taken together, the AHR aids in tissue
protection, repair, and toxin clearance (Figure 2, left).
ENDOGENOUS LIGANDS
We hypothesize that as the adaptive immune system developed, it
became crucial that there be a way for the body to dampen overly
robust responses, thereby preventing reactivity to self-proteins and
ensuing autoimmunity. Kynurenine, the first breakdown product
of tryptophan in the IDO pathway, became the transmitter that
interacts with the AHR in T-cells and enhances the differentia-
tion of Tregs that reduce an immune response. At the same time,
kynurenine also interacts with the AHR in DCs to enhance the
generation of IDO, leading to further tryptophan break down.
This response is self-limited, as once the tryptophan in the inflam-
matory milieu is dissipated, kynurenine is no longer generated
and Treg generation is decreased. This push toward a regulatory
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FIGURE 2 |The AHR as friend and foe. This figure represents the hypothesis
that the AHR can be both protective and pathologic in responding to
endogenous and exogenous ligands. On the left, exposure to inhaled
pollution (as well as ingested or topical) can bind to the AHR in immune cells,
and in an inflammatory setting, lead to increased Th17 differentiation, IL-22
generation, and cytochrome P450 enzyme production. All of these responses
can help protect the host from pathologic inflammation and invasion by
endogenous bacteria. Similarly, in response to endogenous ligands during
inflammation (in the spleen, lymph node, or throughout the body), AHR
ligands can lead to increased IDO production and differentiation of Tregs by
binding of kynurenine to the AHR in T-cells, hence controlling an immune
response. On the right, examples of binding of the AHR leading to increased
pathology are shown. Tumors (in the brain or elsewhere) have been shown to
generate TDO, leading to kynurenine production that binds to the AHR in
tumor cells, causing increased regulation and decreased tumor destruction by
the native immune system. In addition, prolonged exposure to external
pollutants can lead to over-differentiation of Th17 cells and aggravation of
autoimmunity in the lungs, gut, skin, and elsewhere in susceptible people.
response from endogenous ligands makes evolutionary sense, as
internal inflammatory responses would need to be controlled to
prevent damage to surrounding epithelial and parenchymal cells
at the sight of an immune response. Additionally, binding of
the AHR to ligand leads to the generation of IL-22 and engen-
ders epithelial cell homeostasis, proliferation, and anti-microbial
peptide production (30), further protecting the bystander tissue.
EXOGENOUS LIGANDS
In contrast to the role that the AHR plays in regulating autoimmu-
nity when presented with endogenous ligands, at interface organs
such as the lung, gut, and skin, AHR activation leads to an effector
response. At these locations, toxin binding to the AHR in immune
cells leads to Th17 differentiation and a heightened inflamma-
tory response. We view this interaction as a “danger” signal that
allows activation of the immune system at the same time that P450
enzymes are upregulated to metabolize toxins. When a host is pre-
sented with a potentially harmful exposure, early signaling and
activation of the immune system occurs concurrently with ligand
clearance. We believe that this is the role of exogenous activation
of the AHR in immune cells.
It is important to again point out that we do not believe that
endogenous ligands such as kynurenine always favor Treg genera-
tion, and exogenous ligands including fractions of pollution always
favor Th17 differentiation. However, we do believe that in the
in vivo inflammatory milieu where exogenous ligands are exposed
to interface organs during a toxic environmental exposure, Th17
differentiation is favored, and similarly in the endogenous in vivo
milieu of an immune response in the presence of IDO and trypto-
phan, Treg generation is favored. The mechanistic details of these
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effects on T-cell differentiation require further delineation and are
an exciting area of research.
PATHOLOGIC RESPONSE
While we hypothesize that the AHR and its role in the immune
system evolved to be protective, there are examples where this
interaction actually increases pathology. In the setting of an over-
whelming exposure to exogenous ligands, generation of ligands by
tumors, or changes in the microbiome altering physiologic inter-
actions between products of bacteria and receptors in the gut, the
AHR can worsen pathology (Figure 2, right).
CANCER
Certain cancers have developed the ability to evade their own
clearance through use of the AHR. In gliomas, constitutive activa-
tion of tryptophan 2,3-dioxygenase (TDO-2) leads to high levels
of kynurenine production. The TDO-2-derived kynurenine then
acts through the AHR in tumor cells in an autocrine manner and
promotes tumor survival as well as altering the regional immune
response by favoring Treg development. These Tregs hamper the
ability of the immune system to clear the tumor. This is particu-
larly effective as the interaction between kynurenine and T-cells
in the vicinity of the tumor leads to local regulation in the very
location and milieu that the tumor resides in Ref. (31). In addi-
tion, there are some examples in human cancer where the tumors
show increased copies of the AHR (32), which could increase the
autocrine effect of preventing tumor clearance.
AUTOIMMUNITY
The immune system is in a constant balance of regulation and
inflammation, and loss of this equilibrium can lead to pathology.
We hypothesize that exogenous ligands of the AHR found in pollu-
tion can aggravate autoimmune conditions in an AHR-dependent
mechanism. For many years, there has been speculation that envi-
ronmental exposures can aggravate or even cause autoimmune
disease, and a recent analysis of epidemiologic data has supported
this hypothesis. The specific exposures that lead to disease and
the mechanisms through which they impart pathology remain
unclear. Recent data suggest that modulation of the Treg/Th17
balance may be at the center of environmentally induced autoim-
munity. An NIEHS workshop concluded that “dysregulated Th17
activity can lead to pathology” in various autoimmune diseases,
and that both smoking and “AHR binding by aromatic hydro-
carbons favors differentiation of Th17 cells and can exacerbate
autoimmunity” (33). We recently identified that inhaled PM leads
to an increase in Th17-driven inflammation (29). In our resultant
model, when an individual is exposed to inhaled PM for a pro-
longed period of time, there is a shift in the Treg/Th17 balance
toward Th17 cells, aggravating or initiating autoimmunity in sus-
ceptible people. This ubiquitous mechanism will be applicable to
multiple environmentally induced autoimmune diseases.
TRANSPLANT REJECTION
One of the novel theories we have been studying in our lab is
the possibility that exposure to pollution is altering the Treg/Th17
balance and leading to chronic rejection after solid organ trans-
plant. This may be most relevant to lung transplantation, where
the transplanted organ is at the interface with the outside envi-
ronment (34). There is growing evidence that inhaled exposure
to elevated levels of atmospheric pollution, with increased PM,
increases chronic rejection in lung transplants in human beings
(35, 36). Bronchiolitic obliterans syndrome (BOS) is the major
form of chronic rejection in lung transplantation, and it has
been well documented that Th17 cells and the cytokine IL-17 are
required for pathology (37–39). Given the link between IL-17 and
BOS, the fact that pollution accelerates BOS, and our own work
demonstrating that pollutants contain AHR ligands, which favor
a Th17 response, it is possible that the AHR is a key factor in
pollutant accelerated rejection in lung transplantation.
GUT IMMUNITY
Some of the highest impact papers regarding the AHR in the last
couple of years have described the relationship between gut immu-
nity and the AHR. The presence of this receptor is necessary for the
establishment of certain populations of immune cells in the gut.
Furthermore, both dietary ligands of the AHR as well as ligands
produced by gut bacteria interact with and alter the gastrointesti-
nal immune system (40, 41). The healthy microbiome generates
ligands that interact with the AHR to maintain gut immune struc-
ture and stability. Loss of some of these ligand-producing bacteria
may increase the risk of autoimmune colitis (42).
SKIN
The AHR is highly expressed in multiple cell types found in skin.
As skin is one of the organs at the interface with the outside envi-
ronment, it is likely that inflammatory disorders are altered by
interaction with toxins and other environmental factors. A recent
publication did document the protective role of various AHR lig-
ands in reducing inflammation in a model for psoriasis (22). At
the same time, exposure to AHR antagonists increased inflamma-
tion. This is clinically relevant, as it is known that certain toxicants
contain fractions that may inhibit the AHR or cytochrome P450
enzymes, and certain weak AHR agonists actually inhibit activa-
tion by other agonists that may be found in different fractions of
a given exposure (43). This implies that in clinically relevant mix-
tures of chemicals, the overall response could be one of antagonism
of the AHR and worsening of skin inflammation.
AHR MEETS IMMUNOLOGY: FRIEND OR FOE?
So does the relationship between the AHR and the immune system
make us healthier and more able to withstand interactions with
the environment, or leave us at risk for pathologic manipulation
of the immune system in response to external and internal sig-
nals? We assert that the AHR does make us healthier, and allows us
to survive in the environment that currently exists. The relation-
ship of the endogenous ligand kynurenine and the AHR allows a
feedback loop that dampens an immune response to prevent too
much inflammation and autoimmunity, allowing a response to be
self-limited. Exogenous ligands serve as “danger” signals that alert
the immune system to toxic insults from the environment, allow-
ing immune cells to play an early role in containing damage done
by these exposures, helping repair local barriers, and containing
local endogenous infectious exposures. At the same time, there
are examples where disease processes have taken advantage of this
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connection to increase pathology. This scenario, where normal
physiology or “protective” responses become overwhelmed and
lead to increased severity of illness, is well documented in immune
responses to pathology, including systemic inflammatory response
syndrome in response to infection, multiple forms of autoim-
munity, and resistance of cancer to its own destruction. As we
better understand the mechanisms and signals behind the role
of the AHR in the immune system, we will be able to manipu-
late this receptor to treat or prevent diseases as diverse as cancer,
autoimmunity, and transplant rejection.
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